Systematic (IUPAC) name | |
---|---|
1-methyl-3H-imidazole-2-thione | |
Clinical data | |
AHFS/Drugs.com | monograph |
MedlinePlus | a682464 |
Pregnancy cat. | D (US) |
Legal status | ℞-only (US) |
Routes | Oral |
Pharmacokinetic data | |
Bioavailability | 93% |
Protein binding | None |
Metabolism | Hepatic |
Half-life | 5-6 hours |
Excretion | Renal |
Identifiers | |
CAS number | 60-56-0 |
ATC code | H03BB02 |
PubChem | CID 1349907 |
DrugBank | APRD00002 |
ChemSpider | 1131173 |
UNII | 554Z48XN5E |
KEGG | D00401 |
ChEBI | CHEBI:50673 |
ChEMBL | CHEMBL1515 |
Chemical data | |
Formula | C4H6N2S |
Mol. mass | 114.17 g/mol |
SMILES | eMolecules & PubChem |
|
|
Physical data | |
Melt. point | 146 °C (295 °F) |
Solubility in water | 2.75 mg/mL (20 °C) |
(verify) |
(what is this?)
Methimazole (also known as Tapazole or Thiamazole or MMI) is an antithyroid drug[1], and part of the thioamide group.
Contents |
Methimazole is a drug used to treat hyperthyroidism, a condition that usually occurs when the thyroid gland is producing too much thyroid hormone. It may also be taken before thyroid surgery to lower thyroid hormone levels and minimize the effects of thyroid manipulation.
Methimazole inhibits the addition of iodine to thyroglobulin by the enzyme thyroperoxidase, a necessary step in the synthesis of triiodothyronine (T3) and thyroxine (T4).
It does not inhibit the action of the sodium-dependent iodide transporter located on follicular cells' basolateral membranes. Inhibition of this step requires competitive inhibitors such as perchlorate and thiocyanate.
It is important to monitor any symptoms of fever or sore throat while taking methimazole; this could indicate the development of agranulocytosis, an uncommon but severe side effect resulting from a drop in the white blood cell count (to be specific, neutropenia, a deficiency of neutrophils). A complete blood count (CBC) with differential is performed to confirm the suspicion, in which case the drug is discontinued. Administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) may increase recovery.
Other side effects include
Adverse effects may occur for individuals who:
|